Johnson Controls International plc (JCI)
NYSE: JCI · Real-Time Price · USD
143.65
-3.75 (-2.54%)
At close: Jun 5, 2026, 4:00 PM EDT
143.00
-0.65 (-0.45%)
After-hours: Jun 5, 2026, 7:12 PM EDT

Johnson Controls International Earnings Call Transcripts

Fiscal Year 2026

  • Analyst Day 2026

    Strategic focus on data centers and biologics is driving rapid growth, with data center revenue expected to triple its share within five years. Business system transformation is doubling innovation and quadrupling manufacturing output, while high service attach rates and digitalization are compounding lifecycle value.

  • Management outlined progress on strategic priorities, margin improvement, and portfolio optimization, highlighting strong order growth, a record backlog, and ongoing transformation through lean and digital initiatives. North America and India are key growth drivers, with margin normalization expected in two to four years.

  • Orders surged 30% year-over-year with revenue up 6% and adjusted EPS up 45%, driven by strong data center demand and operational improvements. Record backlog and raised guidance signal continued momentum, while the Alloy acquisition and business system rollout enhance future growth prospects.

  • A recent acquisition enhances differentiated technology for data centers, supporting strong order growth and a robust pipeline. Operational improvements and restructuring are driving efficiency, while portfolio management focuses on core strategic areas. Margin expansion and positive investor sentiment are expected.

  • Significant progress has been made in portfolio simplification, margin improvement, and digital transformation, with strong order growth in data centers and pharma. The Alloy acquisition is set to enhance thermal management capabilities, while ongoing cost and service initiatives aim to drive further margin gains.

  • Record orders and backlog, strong revenue and margin expansion, and nearly 40% adjusted EPS growth highlight broad-based demand, especially in data centers and life sciences. Full-year guidance was raised, with robust cash flow and continued operational improvements.

Fiscal Year 2025

Fiscal Year 2024

Fiscal Year 2023

Fiscal Year 2022

Fiscal Year 2021

Fiscal Year 2020

Fiscal Year 2019

Fiscal Year 2018

Fiscal Year 2017

Fiscal Year 2016

Fiscal Year 2015

Powered by